10. Bayer - Top 15 R&D Budgets

Who: Bayer

Based: Germany

2006 Pipeline Budget: $3.58 billion (€2.45)

2007 Pipeline News: Early in 2007 Bayer announced that it would aggressively expand its biotech pipeline, concentrating on new development pacts in cardiology, hematology and oncology. Among its most promising drugs is rivaroxaban, a potential blockbuster anti-clotting therapy that proved considerably more effective than Sanofi-Aventis' Lovenox in a Phase III trial. Bayer expects to file for European approval later this year with an FDA application anticipated in 2008. Other promising new chemical entities include VEGF Trap-Eye for Wet AMD and alemtuzumab for multiple sclerosis, both of which are in Phase III trials. Currently, Bayer has 14 projects in Phase I, 17 projects in Phase II and 19 projects in Phase III. A further 8 projects have already been submitted for marketing authorization.

Pending approval:

> Fosrenol - CKD (Japan)
> rThrombin - Bleeding control
> Rivaroxaban - VTE prevention
> Menostar transdermal - VMS
> E2/LNG - HRT (Japan)
> Magnevist MRA - MRA
> Primovist - MRI
> Avelon - PID/New indications (EU)

Phase III:
> Rivaroxaban - Medical ill
> Rivaroxaban - Stroke prevention in atrial fibriliation
> Rivaroxaban - Deep vein thrombosis
> VEGF Trap-Eye - Wet AMD
> Alemtuzumab - Multiple Sclerosis
> Nexavar - Non-small cell lung cancer
> Nexavar - Melanoma
> Bonefos - Bone Met. prevention in breast cancer
> Yaz - Dysmenhorrea
> YAZ Flex - Fertility Control
> DUB-OC (E2/DNG) - FC - Uterine bleeding
> Mirena - Menorrhagia
> Angeliz low-low - Menopausal Management
> Visanne - Endometrosis
> Yasmin plus - Fertility control
> LCS (ULD LNG) - Fertility control
> Ultravist 370 - CT
> Avelox - Unspecified new indications
> Zevalin - IND/aggr NHL 1st line

Full Pipeline Site: Link

10. Bayer - Top 15 R&D Budgets
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.